Hydromorphone is a strong opioid pain reliever used to treat moderate to severe pain, and is also sometimes used to help manage severe coughs.[2] Dilaudid is currently approved and in use across 35 indications[4].[1]
Dilaudid is one of 473 small molecule programs targeting Mucositis. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
114 competitors in Tics
Dilaudid
Sodium Valproate
Rifadin
Priftin
Nydrazid
Sporanox
Duvyzat
CAB LA
Taltz
DTIC-Dome
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Dec 7, 1992
DILAUDID
NDA NDA019891
Sep 24, 2004
PALLADONE
NDA NDA021044
Nov 9, 2007
DILAUDID
NDA NDA019892
Mar 1, 2010
EXALGO
NDA NDA021217
Jan 16, 2020
DILAUDID
NDA NDA019034
Mar 3, 2023
HYDROMORPHONE HYDROCHLORIDE
NDA NDA200403
Dec 14, 2023
HYDROMORPHONE HYDROCHLORIDE
NDA NDA217812
Sources
Details